Optimal Implementation of Sodium-Glucose-2 Cotransporter Inhibitors in US Heart Failure Patients Estimated to Result in Significant Reduction in Worsening of Heart Failure Events Over 3 Years | Medicine in 2 Minutes
1. In this analytical decision-making model study of 4.8 million adults with heart failure in the United States, the optimal implementation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors over 3 years has been estimated to prevent or delay 630,000 events of worsening heart failure on the left ventricular ejection fraction (LVEF) spectrum, of which approximately 230,000 to …